A Multicenter, Open-Label, Phase 1b Study to Assess the Safety and Define the Maximally Tolerated Dose of Epidural Resiniferatoxin Injection for the Treatment of Intractable Pain Associated With Cancer

Trial Profile

A Multicenter, Open-Label, Phase 1b Study to Assess the Safety and Define the Maximally Tolerated Dose of Epidural Resiniferatoxin Injection for the Treatment of Intractable Pain Associated With Cancer

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Resiniferatoxin (Primary)
  • Indications Cancer pain
  • Focus Therapeutic Use
  • Sponsors Sorrento Therapeutics
  • Most Recent Events

    • 06 Jul 2017 New trial record
    • 29 Jun 2017 According to a Sorrento Therapeutics media release, the U.S. FDA has authorized Investigational New Drug Application (IND) for Resiniferatoxin (RTX).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top